Program
Fluconazole
Also written as “fluconazole”, “Fluconazole 400 mg” and “Diflucan®”.
Its studies are mostly in Meningitis, Cryptococcal · Candidiasis · Candidiasis, Oral · Candidemia · Lymphoma, led by 8 companies.
Drug pageFluconazole: every studyMany companies study it; this page follows only the 37 they lead. All 104 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 260 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Merckits history only | 30 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| AstraZenecaits history only | 20 open or running | phase 1since Mar 20, 2014 | Mar 20, 2014 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jan 13, 2012 | Jan 13, 2012 | none ahead |
| Bayerits history only | 10 open or running | phase 1since Apr 17, 2019 | Apr 17, 2019 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since Jul 26, 2019 | Jul 26, 2019 | none ahead |
| Sutphin Drugsits history only | 10 open or running | early phase 1since Jul 31, 2020 | Jul 31, 2020 | none ahead |
Also a collaborator on its studies: Altasciences, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene and Vicuron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First studies: 3 phase 3 studiesFirst studyNCT00002339, NCT00002277, NCT00001017
- Nov 2, 199916 no phase studiesNCT00002325, NCT00002306, NCT00002305 and 13 more
- Mar 11, 2003Phase 3 study in CandidiasisNCT00056368 · 256 enrolled · United States
- Mar 25, 2008Phase 3 study in Tinea CapitisNCT00645242 · 185 enrolled · United States, Puerto Rico
- May 29, 2008Phase 3 study in Candidiasis, InvasiveNCT00689338 · 216 enrolled · Austria, Belgium, Canada and more
- Aug 3, 2010Phase 3 study in CandidemiaNCT01176058 · 17 enrolled · China
- Jan 28, 2013Phase 3 study in Candidiasis, VulvovaginalNCT01806623 · 157 enrolled · Japan
- Aug 20, 2014Phase 1 study in NeoplasmsNCT02222922 · 138 enrolled · United States, Spain
- Aug 3, 2018Phase 1 study in BioequivalenceNCT03621072 · 36 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule
Studies
All 26 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03621072Bioequivalence · China | 1 | Completed | Jul 20, 2019 | 36 |
| NCT02222922Neoplasms · United States, Spain | 1 | Completed | Nov 5, 2019 | 138 |
| NCT01806623Candidiasis, Vulvovaginal · Japan | 3 | Completed | Nov 22, 2013 | 157 |
| NCT01176058Candidemia · China | 3 | Terminated | Nov 2011 | 17 |
| NCT00689338Candidiasis, Invasive · Austria, Belgium, Canada and more | 3 | Completed | May 2010 | 216 |
| NCT00645242Tinea Capitis · United States, Puerto Rico | 3 | Completed | 185 | |
| NCT00056368Candidiasis · United States | 3 | Completed | 256 | |
| NCT00002339Candidiasis · United States | 3 | Completed | 100 | |
| NCT00002325Mycoses · United States | – | Completed | ||
| NCT00002306Meningitis, Cryptococcal · United States | – | Completed | ||
| NCT00002305Meningitis, Cryptococcal · United States, Canada | – | Completed | ||
| NCT00002304Candidiasis · United States, Canada | – | Completed | ||
| NCT00002294Meningitis, Cryptococcal · United States | – | Completed | ||
| NCT00002282Candidiasis, Oral · United States | – | Completed | ||
| NCT00002277Mycoses · United States | 3 | Completed | ||
| NCT00002113Meningitis, Cryptococcal · United States | – | Completed | 64 | |
| NCT00002112Candidiasis, Oral · United States | – | Completed | ||
| NCT00002077Meningitis, Cryptococcal · United States | – | Completed | ||
| NCT00002076Meningitis, Cryptococcal · United States | – | Completed | ||
| NCT00002075Meningitis, Cryptococcal · United States | – | Completed | ||
| NCT00002074Meningitis, Cryptococcal · United States, Canada | – | Completed | ||
| NCT00002068Meningitis, Cryptococcal · United States, Canada | – | Completed | ||
| NCT00002040Meningitis, Cryptococcal · United States | – | Completed | ||
| NCT00002038Candidiasis · United States | – | Completed | ||
| NCT00002010Meningitis · United States | – | Completed | ||
| NCT00001017Meningitis, Cryptococcal · United States | 3 | Completed | Jul 1991 | 330 |
How it is read
Names in the registry
- “Fluconazole”, 36 entries
- “fluconazole”, 5 entries
- “Fluconazole 400 mg”, 1 entry
- “Diflucan®”, 1 entry
- “Fluconazole 150mg Capsule Localized Originator”, 1 entry
Conditions, from the studies’ own filings
- Meningitis, Cryptococcal, 11 studies
- Candidiasis, 5 studies
- Candidiasis, Oral, 4 studies
- Candidemia, 3 studies
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.